FDA advisory panel narrowly backs multi-cancer blood test amid efficacy doubts
FDA action · Renal & Urology News · 2026-09-28. Number 1 in the UrologyWatch Top 5 for September 29, 2026.
An FDA advisory panel voted to support a multi-cancer early detection blood test despite panelists raising concerns about whether the evidence adequately demonstrates clinical benefit.
Why it matters: Multi-cancer screening tests could affect referral patterns and downstream urologic workup if authorized.
Source: Renal & Urology News
Loading today's edition…